Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372272 | 0.97 | SIGMAR1 (0.33) | SIGMAR1HRH3TSHRALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL20474339 | 0.95 | ATM (0.36) | SIGMAR1HRH3TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL522905 | 0.86 | ALOX15 (0.32) | — | |
| SCHEMBL11715970 | 0.78 | CYP2B6 (0.32) | SIGMAR1HRH3TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL3554595 | 0.78 | — | — | |
| SCHEMBL24891399 | 0.78 | HRH3 (0.39) | SIGMAR1HRH3TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL135698 | 0.78 | HRH3 (0.39) | SIGMAR1HRH3TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL22342735 | 0.78 | HRH3 (0.39) | SIGMAR1HRH3TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL3630893 | 0.78 | HRH3 (0.39) | SIGMAR1HRH3TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL12191564 | 0.78 | HRH3 (0.39) | SIGMAR1HRH3TSHRALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008017755-A2 | LAMELLAR ZIRCONIUM AND/OR TITANIUM PHOSPHATE STRUCTURE MODIFIED BY AN ALKYLAMINE OR A DIAMINE, METHOD OF PREPARATION AND USE THEREOF | RHODIA OPERATIONS (FR) | 2008-02-14 | — | — | WO | claimed |
| CN-119019346-A | Heterocyclic polyamine compound, preparation method and application thereof, and heterocyclic polyamine combined solution | 大连理工大学 | 2024-11-26 | — | — | CN | disclosed |
| EP-3560499-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-1778240-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-1778240-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3560499-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3560499-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-9884063-B2 | Amido-substituted azole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-06 | — | — | US | disclosed |
| WO-2017025901-A1 | NOVEL C28-ANALOGUES WITH C3-MODIFICATIONS OF TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017025901-A1 | NOVEL C28-ANALOGUES WITH C3-MODIFICATIONS OF TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-02-16 | — | — | WO | disclosed |
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| US-20060025411-A1 | Methods for treating diseases or conditions using dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-02-02 | — | — | US | disclosed |
| US-6861422-B2 | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | 2005-01-20 | — | — | US | disclosed |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-20 | — | — | US | disclosed |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| EP-0656353-B1 | Aminochinoline derivates useful in the treatment of malaria | HOFFMANN LA ROCHE (CH) | 1998-06-03 | — | — | EP | disclosed |
| US-5596002-A | TREATMENT OF ANTIBIOTIC RESISTANT MICROORGANISMS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0656353-A1 | Aminochinoline derivates useful in the treatment of malaria | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | disclosed |
| EP-0219706-A1 | N,N-dialkylaminoalkyl-hexahydro-5-oxo-1H-pyrrolizine-3-carboxamides | WARNER-LAMBERT COMPANY (US) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | QDPR, F5, F12 | SIGMAR1 2657/4885HRH3 796/4885TSHR 2184/4885 |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | QDPR, DHPS, DRD5 | SIGMAR1 1676/4885HRH3 1627/4885TSHR 3992/4885 |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | QDPR, DHPS, DHFR | SIGMAR1 3548/4885HRH3 346/4885TSHR 1889/4885 |
| US-20060025411-A1 | Methods for treating diseases or conditions using dihydropteridinone compounds | QDPR, DHPS, DHFR | SIGMAR1 3371/4885HRH3 241/4885TSHR 1980/4885 |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | QDPR, DHPS, DHODH | SIGMAR1 3131/4885HRH3 779/4885TSHR 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.